

**UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
OFFICE OF ADMINISTRATIVE LAW JUDGES**

In the Matter of

**Altria Group, Inc.
a corporation;**

and

**JUUL Labs, Inc.
a corporation.**

Docket No. 9393

**COMPLAINT COUNSEL’S OPPOSITION TO RESPONDENT JUUL LABS, INC.
SECOND MOTION FOR *IN CAMERA* REVIEW OF CERTAIN TRIAL EXHIBITS**

Respondent Juul Labs, Inc. (“JLI” or “Respondent”)’s Second Motion For *In Camera* Review Of Certain Trial Exhibits (“Respondent’s Motion”) has been remarkably paired down compared to its first motion for *in camera* treatment of certain trial exhibits. Nevertheless, for a limited number of documents, Respondent still fails to satisfy the high burden set forth in FTC Rule 3.45. Accordingly, Complaint Counsel renews just a small number of its objections raised in Complaint Counsel’s May 14, 2021 Opposition to JLI’s Motion for *In Camera* Review of Certain Trial Exhibits. Complaint Counsel’s renewed objections are limited to seven documents.¹ Complaint Counsel objects to *in camera* treatment for: RX1991, RX1993, PX2486, and PX2142/RX1565 at page 46. Complaint Counsel further objects to the full *in camera* designation of PX2117/RX1497 at page 32 and requests that this Court order Respondent to

¹ Note that PX2142 and RX1565 are the same document, and PX2117 and RX1497 are the same document. So in effect, Complaint Counsel is only objecting to *in camera* treatment of five documents.

redact page 32 for the limited *in camera* material it contains, and order the rest of the document, aside from page 9, to be public.

LEGAL STANDARD

There is a strong presumption in favor of open access to Commission adjudicative proceedings. Ex. A, *In the Matter of Axon Enterprise, Inc.*, FTC Dkt. 9389, p.2 (Oct. 2, 2020); *In re Polypore Int'l, Inc.*, D-9327, 2009 FTC LEXIS 256, at *3 (April 27, 2009); see also *In re H.P. Hood & Sons, Inc.*, 58 F.T.C. 1184, 1186 (1961) (“To foreclose [FTC] hearings and the evidence adduced therein from the scrutiny of . . . interested persons would serve in large measure to defeat the very reason for our existence.”); *In re Impax Labs, Inc.*, D-9373, 2017 FTC LEXIS 121, at *2 (Oct. 16, 2017). Open proceedings permit the public to evaluate the “fairness of the Commission’s work,” and “provide guidance to persons affected by [the Commission’s] actions.” *In re Intel Corp.*, D-9288, 1999 FTC LEXIS 227, at *1 (Feb. 23, 1999) (citing *The Crown Cork & Seal Co.*, 71 F.T.C. 1714, 1714-15 (1961) and *H.P. Hood*, 58 F.T.C. at 1196).

Under Rule 3.45, Respondent must demonstrate that it will likely suffer “a clearly defined, serious injury” as a result of disclosure. 16 C.F.R. § 3.45(b). The standard for determining “a clearly defined, serious injury” is “based on the standard articulated in *H.P. Hood & Sons, Inc.*, 58 F.T.C. 1184, 1188 (1961).” 16 C.F.R. § 3.45(b) (also citing *Bristol-Myers Co.*, 90 F.T.C. 455, 456 (1977) and *General Foods Corp.*, 95 F.T.C. 352, 355 (1980)). *H.P. Hood* explained that *in camera* requests for ordinary business documents “should be looked upon with disfavor and only granted in exceptional circumstances upon a clear showing that an irreparable injury will result from disclosure.” *H.P. Hood*, 58 F.T.C. 1184, at *14. The Commission found that “the mere fact that respondent prefers to keep them confidential” is not evidence of injury. *H.P. Hood*, 58 F.T.C. 1184, at *13. The potential for embarrassment or the desire to protect

business information that competitors may be “desirous to possess” are not sufficient bases for obscuring material from the public. *H.P. Hood*, 58 F.T.C. 1184, at *14. The motion must also be “narrowly tailored to request *in camera* treatment for only that information that is sufficiently secret and material.” *Polypore*, D-9327, 2009 FTC LEXIS 256, at *4.

ARGUMENT

“The burden rests on Respondent to demonstrate that the evidence sought to be withheld from the public record is sufficiently secret and sufficiently material to its business that disclosure would result in serious competitive injury.” *In re ProMedica Health Sys.*, D-9346, 2011 FTC Lexis 70, at *5-6 (May 13, 2011). Respondent has not met its burden as to a limited number of documents it seeks *in camera* treatment for and Complaint Counsel renews a limited number of objections it filed on May 14, 2021 for seven documents related to Altria’s acquisition of 35% of JLI (“Transaction”) and documents that are or will become more than three years old by the end of next week. Respondent’s motion fails to satisfy Rule 3.45, is overbroad, and makes conclusory claims about competitive injury, as further described below.

I. JLI’S BLANKET CLAIMS RELATED TO THE TRANSACTION, WHICH CLOSED YEARS AGO, SHOULD BE DENIED

First, Respondent again fails to show why public disclosure of stale information relating to the Transaction, which was consummated years ago, and a services agreement that was part of the Transaction that has been almost entirely abandoned, could cause them competitive harm today. *See Ex. A, In the Matter of Axon Enterprise, Inc.*, at 4. Respondent claims that generic dividend, bonus, and cash distribution terms resulting from the Transaction contained in Exhibit B (PX2142/RX1565 at page 46) is sensitive today. Respondent’s Motion at 8. However, this page (46) does not contain the names of any individuals or stockholders and does not show what any specific individual received as a result of the Transaction. Moreover, it has been well

documented in the press that individuals and JLI stockholders were well compensated as a result of the Transaction. *E.g.*, “Juul employees get a special \$2 billion bonus from tobacco giant Altria — to be split among its 1,500 employees,” Angelica LaVito, CNBC.com, Dec. 20, 2018, available at <https://www.cnbc.com/2018/12/20/juul-to-pay-2-billion-dividend-to-its-employees-after-altria-deal.html> (“The bonus averages out to roughly \$1.3 million for each of Juul’s roughly 1,500 employees.”); “Tiger Global Is Said to Get \$1.6 Billion From Altria’s Juul Deal,” Olivia Zelski, Bloomberg.com, Dec. 20, 2018, available at <https://www.bloomberg.com/news/articles/2018-12-20/tiger-global-is-said-to-get-1-6-billion-from-altria-juul-deal> (“Juul shareholders will receive \$150-per-share dividend payout”). The public and impersonal nature of the information contained PX2142/RX1565 at page 46 do not warrant *in camera* treatment.

Complaint Counsel also requests that this Court grant Respondent’s alternative request to redact the *in camera* information in Exhibit C (PX2117/RX1497 at page 32) because Respondent admits that page 32 contains Transaction analysis that it never intended to seek *in camera* treatment for. Respondent’s Motion at 8-9. The portion of this page that Respondent admits does not warrant *in camera* treatment includes {

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED].

II. HISTORICAL DOCUMENTS DO NOT WARRANT *IN CAMERA* TREATMENT

Second, Respondent makes overbroad claims pertaining to documents that – as of the end of the first week of the evidentiary hearing – will be three years old contained in Exhibit D (RX1991, RX1993, PX2486). Respondent fails to meet its burden of demonstrating that it would suffer “a clearly defined, serious injury” as a result of disclosure of a single page of these documents, even though they are effectively three years old and contain information about Altria’s MarkTen e-cigarettes, which were discontinued in late 2018 as a result of the Transaction. Ex. A, *In the Matter of Axon Enterprise, Inc.*, at p.2 (“[T]here is a presumption that *in camera* treatment will not be accorded to information that is more than three years old,” and to overcome that presumption, the movant must demonstrate “demonstrate, by affidavit or declaration, that such material remains competitively sensitive.”); *Impax Labs.*, D-9373, 2017 FTC LEXIS 121, at *3-4. Respondent argues that the competitive landscape is dynamic and has changed since the Transaction, less than three years ago. *See* Scheduling Conference Tr. at 23:6-14. If this were true then JLI could not be seriously injured by information from as late as June 5, 2018, particularly when any analysis includes products that have not existed for years.

Respondent claims its pricing strategies contained in these old documents are relevant today. Respondent’s Motion at 7. Even if that were true, Respondent’s *in camera* requests are overbroad and should not cover the entirety of these documents that contain information about competition that is relevant and material to this proceeding. Moreover, several parts of these documents address pricing strategies related to products that no longer exist. For example in Exhibit D:

- PX2486 { [REDACTED]
- [REDACTED]

[REDACTED]

[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

- Similar material to PX2486 is also included in PX1991 (a June 5, 2018 presentation) and 1993 (a May 2018 presentation).

CONCLUSION

For the aforementioned reasons, Complaint Counsel requests the Court deny Respondent’s requests for *in camera* treatment for RX1991, RX1993, PX2486, PX2142/RX1565 at page 46, and that this Court order Respondent to redact PX2117/RX1497 at page 32 for the limited *in camera* material it contains, and order the rest of PX2117/RX1497, aside from page 9, to be public.

Dated: May 27, 2021

Respectfully submitted,

s/ Nicole Lindquist

Nicole Lindquist

Federal Trade Commission

600 Pennsylvania Avenue, N.W.

Washington, D.C. 20580

Tel: 202-326-3672

NLindquist@ftc.gov

Counsel Supporting the Complaint

EXHIBIT A

**UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
OFFICE OF ADMINISTRATIVE LAW JUDGES**

In the Matter of)	
)	
Axon Enterprise, Inc.)	
a corporation,)	Docket No. 9389
)	
and)	
)	
Safariland, LLC,)	
a partnership,)	
)	
Respondents.)	

**ORDER ON RESPONDENT’S
MOTION FOR *IN CAMERA* TREATMENT**

I.

Pursuant to Rule 3.45(b) of the Rules of Practice of the Federal Trade Commission (“FTC” or “Commission”) and the Scheduling Order entered in this matter, Respondent Axon Enterprise, Inc. (“Respondent” or “Axon”) filed a motion for *in camera* treatment for materials that the parties have listed on their exhibit lists as materials that might be introduced at trial in this matter (“Motion”). Complaint Counsel filed an opposition to the motion (“Opposition”). For the reasons set forth below, Respondent’s motion is GRANTED in part and DENIED WITHOUT PREJUDICE in part.

II.

Under Rule 3.45(b), the Administrative Law Judge may order that material offered into evidence “be placed *in camera* only [a] after finding that its public disclosure will likely result in a clearly defined, serious injury to the person, partnership or corporation requesting *in camera* treatment or [b] after finding that the material constitutes sensitive personal information.” 16 C.F.R. § 3.45(b).

A. Clearly defined, serious injury

“[R]equests for *in camera* treatment must show ‘that the public disclosure of the documentary evidence will result in a clearly defined, serious injury to the person or corporation whose records are involved.’” *In re Kaiser Aluminum & Chem. Corp.*, 103 F.T.C. 500, 500 (1984), quoting *In re H. P. Hood & Sons, Inc.*, 58 F.T.C. 1184, 1961 FTC LEXIS 368 (Mar. 14, 1961). Applicants must “make a clear showing that the information concerned is sufficiently secret and sufficiently material to their business that disclosure would result in serious competitive injury.” *In re General Foods Corp.*, 95 F.T.C. 352, 1980 FTC LEXIS 99, at *10 (Mar. 10, 1980). If the applicants for *in camera* treatment make this showing, the importance of the information in explaining the rationale of FTC decisions is “the principal countervailing consideration weighing in favor of disclosure.” *Id.*

The Federal Trade Commission recognizes the “substantial public interest in holding all aspects of adjudicative proceedings, including the evidence adduced therein, open to all interested persons.” *Hood*, 1961 FTC LEXIS 368, at *5-6. A full and open record of the adjudicative proceedings promotes public understanding of decisions at the Commission. *In re Bristol-Myers Co.*, 90 F.T.C. 455, 458 (1977). A full and open record also provides guidance to persons affected by its actions and helps to deter potential violators of the laws the Commission enforces. *Hood*, 58 F.T.C. at 1186. The burden of showing good cause for withholding documents from the public record rests with the party requesting that documents be placed *in camera*. *Id.* at 1188. Moreover, there is a presumption that *in camera* treatment will not be accorded to information that is more than three years old. *In re Int’l Ass’n of Conference Interpreters*, 1996 FTC LEXIS 298, at *15 (June 26, 1996) (citing *General Foods*, 95 F.T.C. at 353; *Crown Cork*, 71 F.T.C. at 1715).

In order to sustain the burden for withholding documents from the public record, an affidavit or declaration is always required, demonstrating that a document is sufficiently secret and sufficiently material to the applicant’s business that disclosure would result in serious competitive injury. *In re North Texas Specialty Physicians*, 2004 FTC LEXIS 109, at *2-3 (Apr. 23, 2004). To overcome the presumption that *in camera* treatment will not be granted for information that is more than three years old, applicants seeking *in camera* treatment for such documents must also demonstrate, by affidavit or declaration, that such material remains competitively sensitive. In addition, to properly evaluate requests for *in camera* treatment, applicants must provide a copy of the documents at issue to the Administrative Law Judge for review. Where *in camera* treatment is sought for transcripts of investigational hearings or depositions, the requests shall be made only for those specific pages and line numbers of transcripts that contain information that meets the *in camera* standard. *In re Unocal*, 2004 FTC LEXIS 197, *4-5 (Oct. 7, 2004).

Under Commission Rule 3.45(b)(3), indefinite *in camera* treatment is warranted only “in unusual circumstances,” including circumstances in which “the need for confidentiality of the material . . . is not likely to decrease over time. . . .” 16 C.F.R. § 3.45(b)(3). “Applicants seeking indefinite *in camera* treatment must further demonstrate ‘at the outset that the need for confidentiality of the material is not likely to decrease over time’ 54 Fed. Reg. 49,279 (1989) . . .

[and] that the circumstances which presently give rise to this injury are likely to be forever present so as to warrant the issuance of an indefinite *in camera* order rather than one of more limited duration.” *In re E. I. DuPont de Nemours & Co.*, 1990 FTC LEXIS 134, at *2-3 (Apr. 25, 1990). In *DuPont*, the Commission rejected the respondent’s request for indefinite *in camera* treatment. However, based on “the highly unusual level of detailed cost data contained in these specific trial exhibit pages, the existence of extrapolation techniques of known precision in an environment of relative economic stability, and the limited amount of technological innovation occurring in the . . . industry,” the Commission extended the duration of the *in camera* treatment for a period of ten years. *Id.* at *5-6.

In determining the length of time for which *in camera* treatment is appropriate, the distinction between trade secrets and ordinary business records is important because ordinary business records are granted less protection than trade secrets. *Hood*, 58 F.T.C. at 1189. Examples of trade secrets meriting indefinite *in camera* treatment include secret formulas, processes, other secret technical information, or information that is privileged. *Hood*, 58 F.T.C. at 1189; *General Foods*, 95 F.T.C. at 352; *In re Textron, Inc.*, 1991 FTC LEXIS 135, at *1 (Apr. 26, 1991).

In contrast to trade secrets, ordinary business records include information such as customer names, pricing to customers, business costs and profits, as well as business plans, marketing plans, or sales documents. *See Hood*, 1961 FTC LEXIS 368, at *13; *In re McWane, Inc.*, 2012 FTC LEXIS 143 (Aug. 17, 2012); *In re Int’l Ass’n of Conference Interpreters*, 1996 FTC LEXIS 298, at *13-14. When *in camera* treatment is granted for ordinary business records, it is typically provided for two to five years. *E.g.*, *McWane, Inc.*, 2012 FTC LEXIS 143; *In re ProMedica Health Sys.*, 2011 FTC LEXIS 101 (May 25, 2011).

In addition, Respondent’s motion is evaluated by the standards applied in *In re Otto Bock Healthcare N. Am.*, 2018 WL 3491602, at *1 (July 2, 2018).

B. Sensitive personal information

Under Rule 3.45(b) of the Rules of Practice, after finding that material constitutes “sensitive personal information,” the Administrative Law Judge shall order that such material be placed *in camera*. 16 C.F.R. § 3.45(b). “Sensitive personal information” is defined as including, but not limited to, “an individual’s Social Security number, taxpayer identification number, financial account number, credit card or debit card number, driver’s license number, state-issued identification number, passport number, date of birth (other than year), and any sensitive health information identifiable by individual, such as an individual’s medical records.” 16 C.F.R. § 3.45(b). In addition to these listed categories of information, in some circumstances, individuals’ names and addresses, and witness telephone numbers have been found to be “sensitive personal information” and accorded *in camera* treatment. *In re LabMD, Inc.*, 2014 FTC LEXIS 127 (May 6, 2014); *In re McWane, Inc.*, 2012 FTC LEXIS 156 (Sept. 17, 2012). *See also In re Basic Research, LLC*, 2006 FTC LEXIS 14, at *5-6 (Jan. 25, 2006) (permitting the redaction of information concerning particular consumers’ names or other personal data when it

was not relevant). “[S]ensitive personal information . . . shall be accorded permanent *in camera* treatment unless disclosure or an expiration date is required or provided by law.” 16 C.F.R. § 3.45(b)(3).

III.

Respondent’s motion seeks *in camera* treatment for 659 identified trial exhibits, which include documents and testimony that, according to Respondent, fall into five categories: (1) internal pricing information, (2) internal financial and business planning, (3) business strategy information, (4) product security information, and (5) personal information. The large number of documents that Respondent seeks to protect exceeds that which would reasonably be expected to be entitled to the protection contemplated by Rule 3.45. This casts doubt on the claim that all the documents are in fact entitled to such protection. Furthermore, the declaration from Axon’s general counsel offered by Respondent to support its claim provides only general and conclusory justifications.

A review of a sampling of documents reveals that, for many documents, Respondent’s assertion that it would suffer serious competitive harm if the documents were publicly disclosed is unsupported and unpersuasive. For example, Respondent seeks *in camera* treatment for exhibits consisting of board meetings and updates from 2016 that detail plans for 2016 and into 2017, but do not appear to involve plans beyond 2017. Respondent fails to explain why this information is still competitively sensitive. Several pages of one of these exhibits involve details about Axon’s name change, which has already taken place. Some of the information contained therein is already public, such as lists of police departments that are using body worn camera systems. As another example, Respondent seeks *in camera* treatment for a chat transcript from 2015 that discusses an acquisition made by Axon in 2015. It is unclear why this information remains competitively sensitive.

Furthermore, many of the documents for which Respondent seeks *in camera* treatment are over three years old. There is a presumption that *in camera* treatment will not be accorded to information that is more than three years old unless the movant’s supporting declaration shows that such material remains competitively sensitive. Respondent’s supporting declaration fails to provide the necessary justification for granting *in camera* treatment to these documents.

In addition, Respondent seeks *in camera* treatment for a period of ten years for all of the documents at issue. Respondent has made no representations that the documents reveal trade secrets or highly detailed cost data, and are thus the types of documents that warrant ten-year protection, nor otherwise justified its request for an extended duration of *in camera* treatment for all of the documents. Documents reflecting business plans and strategies, contracts and negotiations with customers, customer specific information, market and competitive analyses, and sales and financial information are ordinary business records and generally are not entitled to an extended period of *in camera* treatment.

The following documents are less than one year old and appear to be competitively sensitive. Therefore, *in camera* treatment, for a period of five years, to expire October 1, 2025, is GRANTED for the documents identified as: RX000290, RX000291, RX000300, RX000305,

RX000432, RX000444, RX000464/PX11457, PX10141, PX10402, PX10404, PX10450, PX10459, PX10492, PX10502, PX10511, PX10617, PX10638, PX10642, PX10652, PX10654, PX10666, PX10667, PX10668, PX10670, PX10687, PX10690, PX10823, PX10825, PX10841, PX10847, PX10855, PX10858, PX10889, PX10900, PX10905, PX10908, PX10909, PX10910, PX10926, PX10939, PX10979, PX10981, PX11138, PX11181, PX11354, PX11389, RX000464/PX11457, PX11458, PX11524, PX11533, PX11682, PX11720, PX11721, PX11722, PX11723, PX11724, PX11745, PX11779, PX11791, PX11792, PX11796, PX11797, PX11798, and PX20311.

With respect to transcripts of investigational hearings and deposition testimony, requests for *in camera* treatment shall be made only for those specific pages and line numbers of transcripts that contain information that meets the *in camera* standard. *In re Unocal*, 2004 FTC LEXIS 197, *4-5 (Oct. 7, 2004). Respondent has properly tailored its request to cover only those portions of the transcripts that contain competitively sensitive information. *In camera* treatment, for a period of five years, to expire October 1, 2025, is GRANTED for the following:

RX000433: 67:6-21; 69:18-70:12; 88:23-93:8; 96:6-19; 104:8-22; 109:3-110:7; 111:9-20; 129:20-130:9; 132:11-133:24; 136:2-141:6; 184:3-186:7;
 RX000434: 46:14-48:14; 72:10-22; 87:19-94:6; 94:21-97:20; 112:9-12; 123:16-124:4; 129:1-23; 140:7-141:14; 151:5-153:15; 162:8-163:2; 173:13-14; 181:13-184:13; 188:4-191:12;
 RX000849/PX80001: 34:5-35:4; 42:20-23; 142:15-143:16; 144:2-146:7; 151:20-158:12;
 RX000850/PX80002: 37:2-5; 68:13-74:13; 79:4-7; 79:25; 154:2-156:19; 158:2-12;
 RX000851/PX80003: 67:6-21; 69:18-70:12; 88:23-93:8; 96:6-19; 104:8-22; 109:3-110:7; 111:9-111:20; 129:20-130:9; 132:11-133:24; 136:2-141:6; 184:3-186:7;
 RX000852/PX80004: 46:14-48:14; 72:10-72:22; 87:19-94:6; 94:21-97:20; 112:9-12; 123:16-124:4; 129:1-23; 140:7-141:14; 151:5-153:15; 162:8-163:2; 173:13-14; 181:13-184:13; 188:4-191:12;
 RX000862/PX81007: 30:2-31:19; 94:22-95:19; 140:9-143:11; 148:13-149:7; 193:7-195:22; 197:3-198:12; 222:20-226:5;
 RX000863/PX81008: 13:13-14:19; 48:18-51:3; 23:16-24:15; 29:17-31:21; 51:12-52:11;
 RX000866/PX81011: 180:7-184:17; 205:5; 207:1;
 RX000879/PX81024: 26:15-29:11;
 RX000883/PX81028: 23:20-27:4; 224:20-238:19;
 RX000888/PX81033: 52:10-54:14;
 RX000890/PX81035: 120:12-16; 137:5-138:9; 140:5-25; 141:15-25; 142:1-4; 143:22-25; 144:1-25; 158:2; 179:3-6, 19; 180:9; 187:19-25; 188:9-12; 189:5-15; 190:1-191:10; 196:9-14; 197:16-199:18;
 RX000891/PX81036: 35:1-36:8; 39:15-42:18;
 RX000895/PX81040: 104:24-25; 199:24-200:9; 216:10-231:2; 231:19-240:23; 247:3-8;
 RX000899/PX81044: 114:20-23; 115:19-25; 116:1-9; 160:16-25; 168:1-21; 214:16-18;
 RX000903/PX81048: 155:9-159:12; 162:12-164:9; 245:24-251:24; 257:6-262:4;
 RX000906/PX81051: 16:24-17:21; 27:1-29:2; 73:11-75:9; 81:11-84:21; 184:22-185:13;
 RX000910/PX81060: 82:22-83:8; 87:5-90:3; 100:10-16; 153:7-13; 154:14-163:11; 164:13-169:6; 177:17-178:24; 190:17-191:5.

One of the categories for which Respondent seeks *in camera* treatment is “personal information.” In support of Respondent’s request for *in camera* treatment for documents in this category, the declaration states: “certain documents reflect compensation, including bonus metrics, salaries, and stock options Other documents in this category include personal performance evaluations” Sensitive personal information includes personal financial information and employment arrangements. *In re Otto Bock Healthcare N. Am., Inc.*, 2018 FTC LEXIS 111, *16-17 (F.T.C. July 6, 2018). “[S]ensitive personal information . . . shall be accorded permanent *in camera* treatment unless disclosure or an expiration date is required or provided by law.” 16 C.F.R. § 3.45(b)(3).

Therefore, permanent *in camera* treatment is GRANTED for the following documents containing sensitive personal information: PX10052, PX10084, PX10128, PX10140, PX10187, PX10196, PX10730, PX10915, PX11125, PX11172, PX11229, PX11385, PX11444, PX11466, PX11506, PX11518, PX11529, PX11733, PX11744, and PX20167.

IV.

For all other documents, Respondent’s Motion is DENIED WITHOUT PREJUDICE, and it is hereby ORDERED that Respondent shall have until October 9, 2020 to refile a motion for *in camera* treatment. In advance of filing any such motion, Respondent shall carefully and thoroughly review all documents for which it seeks *in camera* treatment and narrow its requests to only those documents that comply with the Commission’s strict standards for *in camera* treatment and provide a declaration or affidavit that provides sufficient support for any requests. Complaint Counsel shall have until October 14, 2020 to file any opposition. In the event that either party wishes to introduce any document at trial that is the subject of a then-pending motion for *in camera* treatment, provisional *in camera* treatment may be granted until such time as a subsequent order is issued. *See* 16 C.F.R. § 3.45(g).

ORDERED:



D. Michael Chappell
Chief Administrative Law Judge

Date: October 2, 2020

EXHIBIT B

CONFIDENTIAL – REDACTED IN ENTIRETY

EXHIBIT C

CONFIDENTIAL – REDACTED IN ENTIRETY

EXHIBIT D

CONFIDENTIAL – REDACTED IN ENTIRETY

CERTIFICATE OF SERVICE

I hereby certify that on May 27, 2021, I filed the foregoing document electronically using the FTC's E-Filing System, which will send notification of such filing to:

April Tabor
Secretary
Federal Trade Commission
600 Pennsylvania Ave., NW, Rm. H-113
Washington, DC 20580
ElectronicFilings@ftc.gov

The Honorable D. Michael Chappell
Administrative Law Judge
Federal Trade Commission
600 Pennsylvania Ave., NW, Rm. H-110
Washington, DC 20580

I also certify that I delivered via electronic mail a copy of the foregoing document to:

Debbie Feinstein
Robert J. Katerberg
Justin P. Hedge
Francesca M. Pisano
Adam Pergament
Le-Tanya Freeman
Arnold & Porter Kaye Scholer LLP
601 Massachusetts Ave, NW
Washington, DC 20001
Tel: 202-942-5000
debbie.feinstein@arnoldporter.com
robert.katerberg@arnoldporter.com
justin.hedge@arnoldporter.com
francesca.pisano@arnoldporter.com
Adam.Pergament@arnoldporter.com
tanya.freeman@arnoldporter.com

David Gelfand
Jeremy J. Calsyn
Jessica Hollis
Matthew Bachrack
Cleary Gottlieb Steen & Hamilton LLP
2112 Pennsylvania Avenue, NW
Washington, DC 20037
Tel: 202-974-1500
dgelfand@cgsh.com
jcalsyn@cgsh.com
jhollis@cgsh.com
mbachrack@cgsh.com

Counsel for Respondent JUUL Labs, Inc.

Marc Wolinsky
Jonathan Moses
Kevin Schwartz
Adam Goodman
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
Tel: 212-403-1000
MWolinsky@wlrk.com
JMMoses@wlrk.com
KSchwartz@wlrk.com
ALGoodman@wlrk.com

Beth A. Wilkinson
James M. Rosenthal
Hayter Whitman
Wilkinson Stekloff LLP
2001 M Street NW, 10th Floor
Washington, DC 20036
Tel: 202-847-4000
bwilkinson@wilkinsonstekloff.com
jrosenthal@wilkinsonstekloff.com
hwhitman@wilkinsonstekloff.com

Moira Penza
Wilkinson Stekloff LLP
130 W 42nd Street, 24th Floor
New York, NY 10036
Tel: 929-264-7773
mpenza@wilkinsonstekloff.com

Counsel for Respondent Altria Group, Inc.

By: s/ Nicole Lindquist
Nicole Lindquist, Attorney

Counsel Supporting the Complaint

CERTIFICATE FOR ELECTRONIC FILING

I certify that the electronic copy sent to the Secretary of the Commission is a true and correct copy of the paper original and that I possess a paper original of the signed document that is available for review by the parties and the adjudicator.

May 27, 2021

By: s/ Nicole Lindquist
Nicole Lindquist, Attorney